Clinical trials: Endometrial Cancer Recurrent
Endometrial Cancer
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
This research study is studying a drug combination as a possible treatment for endometrial cancer. The drugs involved in this study are: mirvetuximab soravtansine (IMGN853) pembrolizumab
- Trial name
- NCT03835819
- Testing
- Pembrolizumab, IMGN853
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Gynecologic Cancer, Recurrent Uterine Cancer
Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total…
- Conditions
- Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer
- Trial name
- Regynera-RT (NCT07667192)
- Testing
- Reirradiation, Total Ablative Strategy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT03884101)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 195 sites in United States, Argentina and 20 more
- Volunteers
- 842 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Adenoacanthoma, Endometrial Adenocarcinoma
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent endometrial cancer. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor
- Conditions
- Endometrial Adenoacanthoma, Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma
- Trial name
- NCT00025467
- Testing
- thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01132820
- Testing
- Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 87 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.
- Trial name
- NCT00401635
- Testing
- liposomal doxorubicin, carboplatin
- Where
- 4 sites in Italy
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute, Naples
Endometrial Cancer
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1.
- Trial name
- AtTEnd (NCT03603184)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 93 sites in Australia, Austria and 9 more
- Volunteers
- 549 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Endometrial Carcinosarcoma
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma.
- Trial name
- NCT05156268
- Testing
- Pembrolizumab, Olaparib
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Cancer
Study of EV for Recurrent Endometrial Carcinoma
This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy.
- Trial name
- EV-4-EC (NCT07139977)
- Testing
- Enfortumab Vedotin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- William Bradley
Endometrial Neoplasms
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
To test the patient's cancerous tumor to see if it has a FGFR mutation and, if so, to see how their cancer responds to a treatment with the drug ponatinib as well as examine the side effects caused by ponatinib.
- Trial name
- NCT01888562
- Testing
- Ponatinib
- Sponsor
- Washington University School of Medicine
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Endometrial Cancer
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00032162
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- 19 sites in Germany
- Volunteers
- 63 people
- Sponsor
- AGO Study Group
Neoplasms, Endometrial
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
- Trial name
- NCT06897527
- Testing
- Dostarlimab
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
This is a pragmatic, non-inferiority randomized hybrid decentralized clinical trial. The goal of this study is to determine if one year of maintenance immunotherapy (anti-PD1 agent therapy; pembrolizumab or dostarlimab) is…
- Conditions
- Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
- Trial name
- ASCEND-EC-DCT (NCT07867002)
- Testing
- anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair…
- Trial name
- NCT07270666
- Testing
- ctDNA Testing, Blood draw, Surveys
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
Endometrial Cancer
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
- Trial name
- NCT05761951
- Testing
- DKN-01, Pembrolizumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Malignant Neoplasm of Uterus
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer.
- Trial name
- NCT06040970
- Testing
- Sacituzumab, Cisplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai